Stock Price, Quote, News and Profile of ARS PHARMACEUTICALS INC(NASDAQ:SPRY) stock

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (1/14/2025, 8:06:31 PM)

After market: 11.3 -0.06 (-0.53%)

11.36

+0.1 (+0.89%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-25%

Sales Q2Q%N/A

CRS88.7

6 Month7.78%

Overview

Earnings (Last)11-13 2024-11-13/bmo

Earnings (Next)N/A N/A

Ins Owners18.18%

Inst Owners55.79%

Market Cap1.10B

Shares97.19M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts88

Short Float %20.65%

Short Ratio10.6

IPO12-04 2020-12-04

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 146 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Company Info

ARS PHARMACEUTICALS INC

11682 El Camino Real, Suite 120

San Diego CALIFORNIA

P: 18587719307

Employees: 146

Website: https://ars-pharma.com/

SPRY News

2 days ago - Investor's Business DailyBridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

2 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

9 days ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2...

a month ago - ARS Pharmaceuticals, Inc.ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1...

ARS PHARMACEUTICALS INC (SPRY)

Nasdaq Stock Screener

USA Stock Screener